Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
暂无分享,去创建一个
G. Bakris | W. Hsueh | R. Toto | J. Sowers | J. Douglas | K. Tuttle | L. Dworkin | M. Epstein | W. Elliott | M. Williams | K. Tuttle | Murray Epstein | Willa A. Hsueh | Mark B. Williams | Willa Hsueh
[1] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[2] B. Iversen,et al. Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR. , 1998, American journal of physiology. Renal physiology.
[3] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[4] J. Miller,et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. , 1995, Hypertension.
[5] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[6] G. Bakris,et al. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. , 1996, Archives of internal medicine.
[7] M. Ravid,et al. Risk factors for nephropathy in type 2 diabetes mellitus , 1999, Comprehensive therapy.
[8] G. Bakris,et al. Preservation of renal function: the spectrum of effects by calcium-channel blockers. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] T. Greene,et al. Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.
[10] M. Ravid,et al. Effect of an α-Adrenergic Blocker, and ACE Inhibitor and Hydrochlorothiazide on Blood Pressure and on Renal Function in Type 2 Diabetic Patients with Hypertension and Albuminuria , 1998, Nephron.
[11] Barry R. Davis,et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.
[12] G. Bakris,et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. , 1998, Kidney international.
[13] E. Ritz,et al. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. , 1999, Kidney international.
[14] L. Prisant,et al. Verapamil and Nifedipine in Combination for the Treatment of Hypertension , 1994, Journal of clinical pharmacology.
[15] G. Wolf,et al. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension. , 1989, Journal of hypertension.
[16] The Gisen Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.
[17] O. Ifudu. Benefits of Combination Antihypertensive Therapy in Progressive Chronic Renal Failure , 1999 .
[18] G. Eknoyan,et al. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] C. Lewis,et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) , 1997, Hypertension.
[20] M. Lishner,et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. , 1996, Archives of internal medicine.
[21] Bertram Pitt,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.
[22] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .
[23] H. Black,et al. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2000, Archives of internal medicine.
[24] P. Fioretto,et al. Effects of Cilazapril and Amlodipine on Kidney Function in Hypertensive NIDDM Patients , 1996, Diabetes.
[25] C. Mogensen,et al. Renal Factors Influencing Blood Pressure Threshold and Choice of Treatment for Hypertension in IDDM , 1991, Diabetes Care.
[26] L. Prisant,et al. Sexual dysfunction with antihypertensive drugs. , 1994, Archives of internal medicine.
[27] P. Whelton,et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. , 1997, JAMA.
[28] R. Holman,et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. , 1999, Archives of internal medicine.
[29] M. Pahor,et al. Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.
[30] Philip D. Harvey,et al. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.
[31] G. Bakris,et al. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. , 1994, Journal of diabetes and its complications.
[32] G. Bakris,et al. Effects of Sodium Intake on Albumin Excretion in Patients with Diabetic Nephropathy Treated with Long-Acting Calcium Antagonists , 1996, Annals of Internal Medicine.
[33] F. Locatelli,et al. The renoprotective effect of antihypertensive drugs. , 1998, Journal of nephrology.
[34] A. Stewart,et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. , 1997, Archives of internal medicine.
[35] Bruce Neal,et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. , 1999, Journal of hypertension.
[36] R B Haynes,et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[37] R. Toto,et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. , 1996, Controlled clinical trials.
[38] W. Elliott,et al. Circadian variation in the timing of stroke onset: a meta-analysis. , 1998, Stroke.
[39] J. Coope,et al. The prognostic significance of blood pressure in the elderly. , 1988, Journal of human hypertension.
[40] S. Willich,et al. Circadian variation and triggering of cardiovascular events , 1999, Vascular medicine.
[41] O. Pedersen,et al. White Coat Hypertension in NIDDM Patients With and Without Incipient and Overt Diabetic Nephropathy , 1997, Diabetes Care.
[42] B. Davis,et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. , 2001, Controlled clinical trials.
[43] F. Nieto,et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .
[44] Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .
[45] N. Kaplan. J-curve not burned off by HOT study , 1998, The Lancet.
[46] R. Toto,et al. Hypertension in patients with diabetes , 2000, Postgraduate medicine.
[48] G. Remuzzi,et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). , 1998, Journal of the American Society of Nephrology : JASN.
[49] H. Parving,et al. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. , 1997, Kidney international.
[50] I. Wiklund,et al. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. , 1997, Blood pressure.
[51] J. Birkmeyer,et al. The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors , 1999, Annals of Internal Medicine.
[52] R. Bain,et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[53] P Whelton,et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. , 1995, Hypertension.
[54] R. Rodby,et al. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy , 1996, Diabetes Care.
[55] B. Morgenstern,et al. Human blood pressure determination by sphygmomanometry. , 1993, Circulation.
[56] M. Schroll,et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[57] R. Marfella,et al. Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension , 1997, Annals of Internal Medicine.
[58] F. Gudé,et al. Atherosclerosis profile and microalbuminuria in essential hypertension. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[59] E. Ritz,et al. Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.
[60] S. Greenhouse,et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. , 1994, Kidney international.
[61] G. Bakris,et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. , 1997, Hypertension.
[62] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[63] C. Tzourio,et al. Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke. , 1997, Circulation.
[64] Nie Fe. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II) , 1990 .
[65] S. Anderson. Renal Hemodynamic Effects of Calcium Antagonists in Rats With Reduced Renal Mass , 1991, Hypertension.
[66] R B D'Agostino,et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. , 1993, American heart journal.
[67] B Neal,et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. , 1999, Clinical and experimental hypertension.
[68] G. Bakris,et al. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. , 1999, Kidney international.
[69] C. Grim,et al. A curriculum for the training and certification of blood pressure measurement for health care providers. , 1995, The Canadian journal of cardiology.
[70] K. Tuttle,et al. Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[71] M. Laakso,et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.
[72] A. Ojo,et al. Aggressive blood pressure control may eliminate racial disparity in hypertensive renal disease: the hypertension optimal treatment trial (hot study) , 1999 .
[73] G. Bakris,et al. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , 2000, Archives of internal medicine.
[74] C M O'Connor,et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.
[75] K. Resch,et al. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. , 1994, Kidney international.
[76] D. Hilleman. Cost Effectiveness of Combination Therapy , 1999 .
[77] H. Lebovitz,et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. , 1994, Kidney international. Supplement.
[78] M. Pfeffer,et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[79] W. Kannel,et al. Risk stratification in hypertension: new insights from the Framingham Study. , 2000, American journal of hypertension.
[80] A. Levey,et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. , 1997, Hypertension.
[81] R. Schrier,et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.
[82] G. Bakris,et al. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. , 1994, Kidney international.
[83] H. Black,et al. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. , 1996, Hypertension.
[84] G. Bakris,et al. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. , 1999, American journal of hypertension.
[85] G. Bakris,et al. Therapeutic challenges in the obese diabetic patient with hypertension. , 1996, The American journal of medicine.
[86] B. Davis,et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.
[87] R. Schrier,et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.
[88] D. Levy,et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. , 1994, Circulation.
[89] S. Leurgans,et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. , 1996, Kidney international.
[90] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[91] E. B. Tylor. Primitive Culture: Researches Into the Development of Mythology, Philosophy, Religion, Art, and Custom , 1974 .
[92] P. Whelton,et al. Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.
[93] M. Safar,et al. The Diastolic Blood Pressure in Systolic Hypertension , 2000, Annals of Internal Medicine.
[94] G. Bakris. Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. , 1999, Journal of clinical hypertension.
[95] M. Matsuda,et al. Effects of Angiotensin-Converting Enzyme Inhibitors, Ca2+ Channel Antagonists, and α-Adrenergic Blockers on Glucose and Lipid Metabolism in NIDDM Patients With Hypertension , 1995, Diabetes.